Format
Items per page
Sort by

Send to:

Choose Destination

Results: 17

Related Articles by Review for PubMed (Select 18391047)

1.

Tolevamer, an anionic polymer, neutralizes toxins produced by the BI/027 strains of Clostridium difficile.

Hinkson PL, Dinardo C, DeCiero D, Klinger JD, Barker RH Jr.

Antimicrob Agents Chemother. 2008 Jun;52(6):2190-5. doi: 10.1128/AAC.00041-08. Epub 2008 Apr 7.

2.

Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer.

Weiss K.

Int J Antimicrob Agents. 2009 Jan;33(1):4-7. doi: 10.1016/j.ijantimicag.2008.07.011. Epub 2008 Sep 18. Review.

PMID:
18804351
3.

Toxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.

Hussack G, Tanha J.

Toxins (Basel). 2010 May;2(5):998-1018. doi: 10.3390/toxins2050998. Epub 2010 May 7. Review.

4.

Clostridium difficile toxins: mechanism of action and role in disease.

Voth DE, Ballard JD.

Clin Microbiol Rev. 2005 Apr;18(2):247-63. Review.

5.

Tolevamer, an orally administered, toxin-binding polymer for Clostridium difficile-associated diarrhea.

Scheinfeld N, Biggers K.

Curr Opin Investig Drugs. 2008 Aug;9(8):913-24. Review.

PMID:
18666039
6.

Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes.

Rupnik M.

FEMS Microbiol Rev. 2008 May;32(3):541-55. doi: 10.1111/j.1574-6976.2008.00110.x. Epub 2008 Apr 3. Review.

7.

The role of toxin A and toxin B in the virulence of Clostridium difficile.

Carter GP, Rood JI, Lyras D.

Trends Microbiol. 2012 Jan;20(1):21-9. doi: 10.1016/j.tim.2011.11.003. Epub 2011 Dec 7. Review.

PMID:
22154163
8.

Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties.

Barker RH Jr, Dagher R, Davidson DM, Marquis JK.

Aliment Pharmacol Ther. 2006 Dec;24(11-12):1525-34. Review.

9.

The pathogenicity of Clostridium difficile.

Poxton IR, McCoubrey J, Blair G.

Clin Microbiol Infect. 2001 Aug;7(8):421-7. Review.

10.

Theodore E. Woodward Award. How bacterial enterotoxins work: insights from in vivo studies.

Lamont JT.

Trans Am Clin Climatol Assoc. 2002;113:167-80; discussion 180-1. Review.

11.

Processing of Clostridium difficile toxins.

Giesemann T, Egerer M, Jank T, Aktories K.

J Med Microbiol. 2008 Jun;57(Pt 6):690-6. doi: 10.1099/jmm.0.47742-0. Review.

PMID:
18480324
12.

Clostridium difficile toxins: more than mere inhibitors of Rho proteins.

Genth H, Dreger SC, Huelsenbeck J, Just I.

Int J Biochem Cell Biol. 2008;40(4):592-7. doi: 10.1016/j.biocel.2007.12.014. Epub 2008 Jan 5. Review.

PMID:
18289919
13.

Toward a structural understanding of Clostridium difficile toxins A and B.

Pruitt RN, Lacy DB.

Front Cell Infect Microbiol. 2012 Mar 16;2:28. doi: 10.3389/fcimb.2012.00028. eCollection 2012. Review.

14.

How to detect Clostridium difficile variant strains in a routine laboratory.

Rupnik M.

Clin Microbiol Infect. 2001 Aug;7(8):417-20. Review.

15.

The enterotoxicity of Clostridium difficile toxins.

Sun X, Savidge T, Feng H.

Toxins (Basel). 2010 Jul;2(7):1848-80. doi: 10.3390/toxins2071848. Epub 2010 Jul 14. Review.

16.

Clostridium difficile toxins: mediators of inflammation.

Shen A.

J Innate Immun. 2012;4(2):149-58. doi: 10.1159/000332946. Epub 2012 Jan 10. Review.

17.

Hyperimmune bovine colostrum for treatment of GI infections: a review and update on Clostridium difficile.

Steele J, Sponseller J, Schmidt D, Cohen O, Tzipori S.

Hum Vaccin Immunother. 2013 Jul;9(7):1565-8. doi: 10.4161/hv.24078. Epub 2013 Feb 22. Review.

PMID:
23435084
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk